Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 20/100

ADMA LEGAL NOTICE: ADMA Biologics, Inc. is being Investigated for Securities Fraud after Auditor Resignation; Investors with Losses are Urged to Contact BFA Law (Nasdaq:ADMA)

Key Takeaway: ADMA Biologics, Inc. is currently under investigation for potential securities fraud following the abrupt resignation of its auditor, CohnReznick LLP, which led to a more than 20% decline in its stock price. The leading securities law firm, Bleichmar Fonti & Auld LLP, is urging investors to come forward if they have experienced losses. This situation raises significant concerns about the company's compliance with federal securities laws and its impact on shareholder value.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics faced a significant stock price drop of over 20% following the resignation of its independent outside auditor.
  • The company is under investigation for potential violations of federal securities laws, causing concern among investors.
  • Shareholders may be facing legal options due to the impact of these developments on stock value.

Full Press Release Details

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Why Did ADMA Biologics’s Stock Drop?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
If you invested in ADMA Biologics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.

Tags

Frequently Asked Questions

What is ADMA Biologics known for?

ADMA Biologics develops specialty biologics for immunodeficient patients.

Why did ADMA Biologics stock drop recently?

The stock dropped due to the unexpected resignation of their auditor, CohnReznick LLP.

How much did ADMA Biologics stock decline on October 10, 2024?

ADMA Biologics stock fell by more than 20% during trading on October 10, 2024.

What should ADMA Biologics investors do now?

Investors are urged to gather more information and explore legal options.

Who is Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a top law firm representing securities plaintiffs.

Last updated: Oct 15, 2024